FDMT Historical Income Statement
| FDMT Stock | USD 7.87 0.37 4.93% |
Historical analysis of 4D Molecular income statement accounts such as Depreciation And Amortization of 4.2 M or Interest Expense of 7.7 M can show how well 4D Molecular Therapeutics performed in making a profits. Evaluating 4D Molecular income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of 4D Molecular's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining 4D Molecular Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether 4D Molecular Therapeutics is a good buy for the upcoming year.
FDMT |
About FDMT Income Statement Analysis
4D Molecular Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to 4D Molecular shareholders. The income statement also shows FDMT investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
4D Molecular Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts 4D Molecular Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of 4D Molecular Therapeutics. It is also known as 4D Molecular overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from 4D Molecular's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into 4D Molecular Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At this time, 4D Molecular's Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 9.6 M in 2024, whereas Total Revenue is likely to drop slightly above 12.9 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 137K | 2.6M | 9.2M | 9.6M | Net Interest Income | 137K | 2.6M | 9.2M | 9.6M |
4D Molecular income statement Correlations
Click cells to compare fundamentals
4D Molecular Account Relationship Matchups
High Positive Relationship
High Negative Relationship
4D Molecular income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 1.5M | 152K | 137K | 2.6M | 9.2M | 9.6M | |
| Interest Income | 1.5M | 152K | 137K | 2.6M | 9.2M | 9.6M | |
| Depreciation And Amortization | 11.3M | 1.4M | 3.0M | 3.9M | 5.7M | 4.2M | |
| Selling General Administrative | 13.9M | 17.2M | 28.0M | 32.9M | 36.5M | 21.7M | |
| Total Revenue | 7.0M | 13.6M | 18.0M | 3.1M | 20.7M | 12.9M | |
| Gross Profit | (31.7M) | (39.4M) | 18.0M | 3.1M | (76.4M) | (72.6M) | |
| Other Operating Expenses | 52.6M | 70.3M | 89.4M | 113.2M | 133.6M | 78.7M | |
| Operating Income | (50.8M) | (56.7M) | (71.3M) | (110.0M) | (112.9M) | (107.2M) | |
| Net Income From Continuing Ops | (49.3M) | (56.7M) | (71.3M) | (107.5M) | (95.9M) | (91.1M) | |
| Ebit | (50.8M) | (56.7M) | (71.3M) | (110.0M) | (112.9M) | (107.2M) | |
| Research Development | 38.7M | 53.0M | 61.4M | 80.3M | 97.1M | 56.9M | |
| Ebitda | (39.5M) | (55.2M) | (68.3M) | (106.2M) | (107.1M) | (101.8M) | |
| Total Operating Expenses | 52.6M | 70.3M | 89.4M | 113.2M | 133.6M | 78.7M | |
| Reconciled Depreciation | 1.0M | 1.4M | 3.0M | 3.9M | 5.6M | 5.9M | |
| Income Before Tax | (49.3M) | (56.7M) | (71.3M) | (107.5M) | (100.8M) | (95.8M) | |
| Total Other Income Expense Net | 1.5M | (29K) | 16K | 2.5M | 12.0M | 12.6M | |
| Net Income Applicable To Common Shares | (49.3M) | (56.7M) | (71.3M) | (107.5M) | (96.7M) | (91.9M) | |
| Net Income | (52.9M) | (56.5M) | (68.3M) | (101.1M) | (100.8M) | (95.8M) | |
| Income Tax Expense | 3.6M | (152K) | (3.0M) | (6.4M) | 5.6M | 5.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.